乳腺癌内分泌治疗耐药的机制研究进展

doi:10.3760/cma.j.cn371439-20221123-00070

摘要/Abstract

摘要：

内分泌治疗耐药是激素受体阳性乳腺癌治疗过程中一个主要的挑战。近年来内分泌耐药机制主要聚焦于ESR1突变或融合、表观遗传学调控、信号转导通路调控异常、细胞周期调控、肿瘤干细胞、代谢重编程、肿瘤微环境和自噬。探讨乳腺癌内分泌治疗耐药机制的最新进展，可为激素受体阳性乳腺癌精准治疗提供更多的研究思路和治疗选择。

关键词: 乳腺肿瘤, 受体, 雌激素, 抗药性, 内分泌治疗

Abstract:

Endocrine therapy resistance is a major challenge in the treatment of hormone receptor-positive breast cancer. In recent years，endocrine resistance mechanisms have focused on ESR1 mutations or fusions，epigenetic regulation，abnormal regulation of signal transduction pathway，cell cycle regulation，cancer stem cells，metabolic reprogramming，tumor microenvironment and autophagy. Exploring the latest advances in the mechanisms of endocrine therapy resistance in breast cancer may provide more research ideas and treatment options for the precision treatment of hormone receptor-positive breast cancer.

Key words: Breast neoplasms, Receptors, estrogen, Drug resistance, Endocrine therapy

王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.

Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.

参考文献 43

[1]	Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial[J]. Lancet Oncol, 2010, 11(12): 1135-1141. DOI: 10.1016/S1470-2045(10)70257-6. doi: 10.1016/S1470-2045(10)70257-6 pmid: 21087898
[2]	Clatot F, Perdrix A, Beaussire L, et al. Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer[J]. Breast Cancer Research, 2020, 22(1): 56. DOI: 10.1186/s13058-020-01290-x. doi: 10.1186/s13058-020-01290-x pmid: 32466779
[3]	Jeselsohn R, Bergholz JS, Pun M, et al. Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations[J]. Cancer Cell, 2018, 33(2): 173-186. e5. DOI: 10.1016/j.ccell.2018.01.004. doi: S1535-6108(18)30004-7 pmid: 29438694
[4]	Hartmaier RJ, Trabucco SE, Priedigkeit N, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer[J]. Ann Oncol, 2018, 29(4): 872-880. DOI: 10.1093/annonc/mdy025. doi: S0923-7534(19)45471-9 pmid: 29360925
[5]	Li L, Lin L, Veeraraghavan J, et al. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance[J]. Breast Cancer Res, 2020, 22(1): 84. DOI: 10.1186/s13058-020-01325-3. doi: 10.1186/s13058-020-01325-3 pmid: 32771039
[6]	Sun G, Wang C, Wang S, et al. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer[J]. Nucleic Acids Res, 2020, 48(19): 10768-10784. DOI: 10.1093/nar/gkaa787. doi: 10.1093/nar/gkaa787 pmid: 32986841
[7]	Achinger-Kawecka J, Valdes-Mora F, Luu PL, et al. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer[J]. Nat Commun, 2020, 11(1): 320. DOI: 10.1038/s41467-019-14098-x. doi: 10.1038/s41467-019-14098-x pmid: 31949157
[8]	Nassa G, Salvati A, Tarallo R, et al. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells[J]. Sci Adv, 2019, 5(2): eaav5590. DOI: 10.1126/sciadv.aav5590. doi: 10.1126/sciadv.aav5590
[9]	Linares A, Assou S, Lapierre M, et al. Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers[J]. Mol Oncol, 2019, 13(7): 1534-1547. DOI: 10.1002/1878-0261.12505. doi: 10.1002/1878-0261.12505 pmid: 31099456
[10]	Yu S, Gong X, Ma Z, et al. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage[J]. Cell Oncol (Dordr), 2020, 43(1): 65-80. DOI: 10.1007/s13402-019-00439-x. doi: 10.1007/s13402-019-00439-x
[11]	Jiang Z, Li W, Hu X, et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(6): 806-815. DOI: 10.1016/S1470-2045(19)30164-0. doi: S1470-2045(19)30164-0 pmid: 31036468
[12]	Peng WX, Koirala P, Zhou H, et al. Lnc-DC promotes estrogen Independent growth and tamoxifen resistance in breast cancer[J]. Cell Death Dis, 2021, 12(11): 1000. DOI: 10.1038/s41419-021-04288-1. doi: 10.1038/s41419-021-04288-1
[13]	Feng J, Wen T, Li Z, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/CDK2 axis promotes progression of ER⁺ breast cancer and confers tamoxifen resistance[J]. Aging (Albany NY), 2020, 12(20): 20658-20683. DOI: 10.18632/aging.103966. doi: 10.18632/aging.103966
[14]	Li J, Lu M, Jin J, et al. miR-449a suppresses tamoxifen resistance in human breast cancer cells by targeting ADAM22[J]. Cell Physiol Biochem, 2018, 50(1): 136-149. DOI: 10.1159/000493964. doi: 10.1159/000493964 pmid: 30278449
[15]	Croessmann S, Formisano L, Kinch LN, et al. Combined blockade of activating ERBB2 mutations and ER results in synthetic lethality of ER⁺/HER2 mutant breast cancer[J]. Clin Cancer Res, 2019, 25(1): 277-289. DOI: 10.1158/1078-0432.CCR-18-1544. doi: 10.1158/1078-0432.CCR-18-1544 pmid: 30314968
[16]	Ribas R, Pancholi S, Rani A, et al. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer[J]. Breast Cancer Res, 2018, 20(1): 44. DOI: 10.1186/s13058-018-0983-1. doi: 10.1186/s13058-018-0983-1 pmid: 29880014
[17]	Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20. DOI: 10.1056/NEJMoa2203690. doi: 10.1056/NEJMoa2203690
[18]	Choi HJ, Joo HS, Won HY, et al. Role of RBP2-induced ER and IGF1R-ErbB signaling in tamoxifen resistance in breast cancer[J]. J Natl Cancer Inst, 2018, 110(4): 400-410. DOI: 10.1093/jnci/djx207. doi: 10.1093/jnci/djx207
[19]	Nagle AM, Levine KM, Tasdemir N, et al. Loss of E-cadherin enhances IGF1-IGF1R pathway activation and sensitizes breast cancers to anti-IGF1R/InsR inhibitors[J]. Clin Cancer Res, 2018, 24(20): 5165-5177. DOI: 10.1158/1078-0432.CCR-18-0279. doi: 10.1158/1078-0432.CCR-18-0279 pmid: 29941485
[20]	Drago JZ, Formisano L, Juric D, et al. FGFR1 amplification me-diates endocrine resistance but retains TORC sensitivity in metastatic hormone receptor-positive (HR⁺) breast cancer[J]. Clin Cancer Res, 2019, 25(21): 6443-6451. DOI: 10.1158/1078-0432.CCR-19-0138. doi: 10.1158/1078-0432.CCR-19-0138
[21]	Walsh L, Haley KE, Moran B, et al. BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer[J]. Clin Cancer Res, 2019, 25(23): 7139-7150. DOI: 10.1158/1078-0432.CCR-19-0713. doi: 10.1158/1078-0432.CCR-19-0713 pmid: 31409615
[22]	Jacquemetton J, Kassem L, Poulard C, et al. Analysis of genomic and non-genomic signaling of estrogen receptor in PDX models of breast cancer treated with a combination of the PI3K inhibitor alpelisib (BYL719) and fulvestrant[J]. Breast Cancer Res, 2021, 23(1): 57. DOI: 10.1186/s13058-021-01433-8. doi: 10.1186/s13058-021-01433-8 pmid: 34020697
[23]	André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1[J]. Ann Oncol, 2021, 32(2): 208-217. DOI: 10.1016/j.annonc.2020.11.011. doi: 10.1016/j.annonc.2020.11.011 pmid: 33246021
[24]	Dent S, Cortés J, Im YH, et al. Phase Ⅲ randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial[J]. Ann Oncol, 2021, 32(2): 197-207. DOI: 10.1016/j.annonc.2020.10.596. doi: 10.1016/j.annonc.2020.10.596 pmid: 33186740
[25]	Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target[J]. Oncotarget, 2018, 9(48): 28989-29006. DOI: 10.18632/oncotarget.25615. doi: 10.18632/oncotarget.25615 pmid: 29989029
[26]	Vidula N, Yau C, Rugo H. Trophoblast cell surface antigen 2 gene (TACSTD2) expression in primary breast cancer[J]. Breast Cancer Res Treat, 2022, 194(3): 569-575. DOI: 10.1007/s10549-022-06660-x. doi: 10.1007/s10549-022-06660-x
[27]	Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2022, 40(29): 3365-3376. DOI: 10.1200/JCO.22.01002. doi: 10.1200/JCO.22.01002
[28]	Pancholi S, Ribas R, Simigdala N, et al. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities[J]. Oncogene, 2020, 39(25): 4781-4797. DOI: 10.1038/s41388-020-1284-6. doi: 10.1038/s41388-020-1284-6 pmid: 32307447
[29]	Kettner NM, Vijayaraghavan S, Durak MG, et al. Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer[J]. Clin Cancer Res, 2019, 25(13): 3996-4013. DOI: 10.1158/1078-0432.CCR-18-3274. doi: 10.1158/1078-0432.CCR-18-3274 pmid: 30867218
[30]	Alves CL, Ehmsen S, Terp MG, et al. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer[J]. Nat Commun, 2021, 12(1): 5112. DOI: 10.1038/s41467-021-25422-9. doi: 10.1038/s41467-021-25422-9 pmid: 34433817
[31]	Bardia A, Hurvitz SA, DeMichele A, et al. Phase Ⅰ/Ⅱ trial of exemestane, ribociclib, and everolimus in women with HR⁺/HER2^-advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1)[J]. Clin Cancer Res, 2021, 27(15): 4177-4185. DOI: 10.1158/1078-0432.CCR-20-2114. doi: 10.1158/1078-0432.CCR-20-2114
[32]	Santiago-Gómez A, Kedward T, Simões BM, et al. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer[J]. Cancer Lett, 2019, 458: 66-75. DOI: 10.1016/j.canlet.2019.05.014. doi: S0304-3835(19)30309-X pmid: 31121213
[33]	Simões BM, Santiago-Gómez A, Chiodo C, et al. Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer[J]. Oncogene, 2020, 39(25): 4896-4908. DOI: 10.1038/s41388-020-1335-z. doi: 10.1038/s41388-020-1335-z pmid: 32472077
[34]	Mavingire N, Campbell P, Wooten J, et al. Cancer stem cells: culprits in endocrine resistance and racial disparities in breast cancer outcomes[J]. Cancer Lett, 2021, 500: 64-74. DOI: 10.1016/j.canlet.2020.12.014. doi: 10.1016/j.canlet.2020.12.014 pmid: 33309858
[35]	Piggott L, Silva A, Robinson T, et al. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through posttranslational downregulation of c-FLIP[J]. Clin Cancer Res, 2018, 24(10): 2452-2463. DOI: 10.1158/1078-0432.CCR-17-1381. doi: 10.1158/1078-0432.CCR-17-1381 pmid: 29363524
[36]	Bacci M, Lorito N, Ippolito L, et al. Reprogramming of amino acid transporters to support aspartate and glutamate dependency sustains endocrine resistance in breast cancer[J]. Cell Rep, 2019, 28(1): 104-118. e8. DOI: 10.1016/j.celrep.2019.06.010. doi: S2211-1247(19)30768-5 pmid: 31269432
[37]	He M, Jin Q, Chen C, et al. The miR-186-3p/EREG axis orchestrates tamoxifen resistance and aerobic glycolysis in breast cancer cells[J]. Oncogene, 2019, 38(28): 5551-5565. DOI: 10.1038/s41388-019-0817-3. doi: 10.1038/s41388-019-0817-3 pmid: 30967627
[38]	Gökmen-Polar Y, Neelamraju Y, Goswami CP, et al. Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways[J]. EMBO Rep, 2019, 20(2): e46078. DOI: 10.15252/embr.201846078. doi: 10.15252/embr.201846078
[39]	Morotti M, Bridges E, Valli A, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer[J]. Proc Natl Acad Sci U S A, 2019, 116(25): 12452-12461. DOI: 10.1073/pnas.1818521116. doi: 10.1073/pnas.1818521116
[40]	Joffroy CM, Buck MB, Stope MB, et al. Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer[J]. Cancer Res, 2010, 70(4): 1314-1322. DOI: 10.1158/0008-5472.CAN-09-3292. doi: 10.1158/0008-5472.CAN-09-3292 pmid: 20145137
[41]	Anurag M, Zhu M, Huang C, et al. Immune checkpoint profiles in luminal B breast cancer (alliance)[J]. J Natl Cancer Inst, 2020, 112(7): 737-746. DOI: 10.1093/jnci/djz213. doi: 10.1093/jnci/djz213 pmid: 31665365
[42]	Yang F, Xie HY, Yang LF, et al. Stabilization of MORC2 by estrogen and antiestrogens through GPER1-PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells[J]. Autophagy, 2020, 16(6): 1061-1076. DOI: 10.1080/15548627.2019.1659609. doi: 10.1080/15548627.2019.1659609 pmid: 32401166
[43]	Actis C, Muzio G, Autelli R. Autophagy triggers tamoxifen resistance in human breast cancer cells by preventing drug-induced lysosomal damage[J]. Cancers (Basel), 2021, 13(6): 1252. DOI: 10.3390/cancers13061252. doi: 10.3390/cancers13061252